Silicon Valley-Based InterVenn BioSciences Raises RM 39 Million, Establishes Subsidiary in Malaysia to Develop Ovarian Cancer Early Detection Blood Test in Collaboration with TPM and CRM

KUALA LUMPUR, Dec 14 (Bernama) — InterVenn BioSciences, a biotech company innovating cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, announced this week an institutional investment of US$9.4 million led by San Francisco-based biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV.

Headquartered in Silicon Valley, USA, InterVenn has established subsidiaries in Kuala Lumpur and Manila to foster biotechnology, drive AI adoption, and support Industrial Revolution 4.0 in Southeast Asia. The company is conducting analytical and clinical validation of its ovarian cancer diagnostic blood test. A global, multi-site clinical study to validate this test will commence in early 2019. Clinical Research Malaysia (CRM), an agency under the Malaysia Ministry of Health, plays a vital role in supporting InterVenn’s clinical operations in Malaysia and facilitated fifteen clinical sites across nine states in Malaysia for this clinical study.

InterVenn’s established strategic partnership with Technology Park Malaysia (TPM) in 2017, an agency under the Malaysia Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), to build an internationally-certified clinical laboratory, attract and upskill a critical scientific talent pool in Malaysia.

Once clinical validation and regulatory processes are completed, the ovarian cancer blood test will be offered as a laboratory diagnostic test. “Today, early diagnosis of ovarian cancer is extremely poor, despite its role in significantly improving survival rates,” said Aldo Carrascoso, CEO of InterVenn BioSciences. “We’ve established a talented team of experts in AI, computational biology, mass spectrometry, glycoproteomics, and product development who are dedicated to equipping physicians with a reliable tool to change the narrative around ovarian cancer. ”

“InterVenn’s decision to conduct their clinical study in Malaysia is testament to the country’s capabilities in terms of infrastructure, good clinical practice, certified investigators and a large patient pool,” said Dr. Akhmal Yusof, CEO of Clinical Research Malaysia. “InterVenn can capitalize on the services that CRM provides to ensure smooth conduct and delivery of their trials. I’m proud that Malaysia will be the first country in Asia that will start this clinical study next year and hopefully Malaysia can contribute to InterVenn’s exponential growth further in the near future.”

Meanwhile, TPM Acting President/CEO, Encik Sharbani Harun said that the collaborative efforts between InterVenn and TPM marked an important milestone for Malaysia to become a central hub for the Asia-Pacific region, towards the advancement of research and development in the field of biomedical and life sciences. “We are certainly proud to be given the opportunity to work closely with InterVenn whereby they will be the utilizing our world-class laboratory equipment and facilities to further their cancer diagnostic innovation,” added Sharbani.

InterVenn aims to lead the next wave of precision medicine by enabling innovation in diagnostics and therapeutics through global collaborations to improve human health. The partnership with TPM and CRM serve as a launchpad for this mission.

–BERNAMA

CRM Becomes First Southeast Asia Research Organisation to Join IQVIA’s Global EPON

Seating L-R: Mr. Teck Kwang Koh, General Manager at IQVIA Malaysia and Dr. Akhmal Yusof. Standing L-R: Dr Voon Pei Jye, Mr. Desmond Dorairajoo, Dato’ Dr. Goh Pik Pin and Mr. David Horsburgh.

KUALA LUMPUR, 28 November 2018 – Clinical Research Malaysia (CRM) today signed a memorandum of understanding (MoU) to establish a strategic alliance with IQVIA’s global Early Phase Oncology Network (EPON).

The agreement makes Clinical Research Centre at Sarawak General Hospital the first in Southeast Asia to be part of IQVIA’s prestigious network of globally qualified Phase I oncology sites. CRM, established by the Malaysian Ministry of Health in 2012, exists to advance Malaysia’s ability to contribute to global health solutions. IQVIA is a leading global provider of contract research services, advanced analytics and technology solutions to the life-sciences industry.

“This agreement is a major step forward for the country of Malaysia to provide advanced Phase I studies for investigational cancer therapies,” said CRM Chief Executive Officer Dr Akhmal Yusof.  “Advances in genomics offer new hope for targeted oncology products. Through this agreement, Sarawak General Hospital will join IQVIA’s global Early Phase Oncology Network, which is designed to provide fast, high-quality Phase I oncology studies to biopharmaceutical companies.”

IQVIA Asia Pacific President Anand Tharmaratnam said: “This agreement builds upon our long relationship with Clinical Research Malaysia as an IQVIA Prime Site.  Adding Sarawak General Hospital’s research centre gives biopharma companies, for the first time, a Southeast Asia location as part of IQVIA’s global network of high quality early phase oncology research sites.  This is a significant step forward in our joint mission to accelerate the development of targeted oncology therapies in Malaysia and Asia for the benefit of patients worldwide.”

IQVIA has been conducting oncology early clinical research in Asia Pacific for more than two decades.  The IQVIA EPON-Clinical Research Malaysia strategic alliance is designed to streamline study startup, enhance consistency, and deliver high-quality results faster.

This collaboration is intended significantly improve the quality of early phase oncology trials in Malaysia by having innovative investigational therapies as an option for patients. This aligns with the Phase I Realization Project (P1RP) that was launched by CRM in 2016 which is focused in enhancing Malaysia’s early phase clinical research capacity and building a more attractive early phase clinical research ecosystem.

The MoU is signed between Dr Akhmal Yusof and on behalf of IQVIA, Mr. Teck Kwang Koh, General Manager at IQVIA Malaysia. The signing of the MoU was witnessed by the Director of Network of Clinical Research Centre, YBhg. Dato’ Dr. Goh Pik Pin, Dr Voon Pei Jye of Sarawak General Hospital, Mr. Desmond Dorairajoo, Head of Academic Research Group Asia-Pacific IQVIA and Mr. David Horsburgh, Asia Strategy Lead, Academic Research Group Asia-Pacific IQVIA.

About CRM

Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.

 

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.To learn more, visit www.iqvia.com.

BERNAMA

Japanese Pharmaceutical Companies Show Interest to Conduct Clinical Trials in Malaysia

TOKYO, 6 November 2018 – Clinical Research Malaysia (CRM) hold a half-day seminar that targets Japanese pharmaceutical and medical device companies interested in conducting clinical trials in the Asian region. This is the first time for CRM to deliver a clinical trial seminar focusing on its home country in Japan.

Read more

Embracing Digital Health

L-R: YBrs. Dr. Kalaiarasu M. Periasamy, Deputy Director, National Clinical Research Centre, Y.Bhg. Datuk Dr. Shahnaz Murad, Deputy General-Director of Health Malaysia (Research & Technical Support), YB. Dr. Lee Boon Chye, Deputy Minister of Health, YBrs. Dr. Akhmal Yusof, CEO of Clinical Research Malaysia, YBhg. Dato’ Dr. Goh Pik Pin, Director National Clinical Research Malaysia

KUALA LUMPUR, 24 September 2018 – The 12thNational Conference for Clinical Research (NCCR) brought together medical experts and researchers under one platform to understand the way digital technology can impact the Malaysian healthcare delivery system, thus potentially improving patient outcomes.

Read more

Celebrating Clinical Research Through the Clinical Trials Day 2018 & 2nd IKN Research Day

PUTRAJAYA, 5 September 2018 – Clinical Trials Day 2018 was held at the Institut Kanser Negara (IKN), its second time since its initiation last year, to celebrate patients, volunteers and medical professionals involved in clinical trials. Clinical Research Malaysia (CRM) partnered with Clinical Research Centre (CRC) and IKN to organise this momentous event in conjunction of IKN’s 5th anniversary.

Read more

Clinical Research Malaysia Forms Two Global Partnerships and New Foreign Investments

L-R: Dr. Akhmal Yusof (CEO of CRM), Mr. Zabidi Mahbar (Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA), YBhg Datuk Dr. Noor Hisham Abdullah (Director General of Health, Malaysia), Dr. Hytham Al-Masri (President & CEO of Hematogenix) and Dr. Yooni Kim (Executive Director, Asia Operations, Novotech)

PUTRAJAYA, 20 April 2018 – Hematogenix, a global leader in integrated laboratory services, and Novotech, Australia’s largest independent contract research organization (CRO) have both signed a Memorandum of Understanding with Clinical Research Malaysia (CRM) to establish strategic partnerships in clinical research.

Read more

Clinical Research Malaysia Sets New Partnership In Japan

TOKYO, 23 March 2018 – intellim Corporation and Clinical Research Malaysia (CRM) have signed a Memorandum of Understanding (MoU) to establish a new strategic partnership between both companies in clinical research. The inking of this MoU spells out support on clinical research activities in both Malaysia and Japan, as well as in business development and networking opportunities for both organizations.

Read more

Encouraging New Clinical Research Collaborations between Malaysia & China

Hangzhou, 30 January – The First Affiliated Hospital of Zhejiang University and Clinical Research Malaysia (CRM) have signed a Memorandum of Understanding (MoU) to collaborate in clinical trial activities in Malaysia and China, today.

The First Affiliated Hospital of Zhejiang University is one of the oldest university in China with a long history in medical research and development. With this cooperation, both parties will provide support and valuable resources to encourage new clinical research collaborations. In addition, it opens teaching and training opportunities, this is also in line with the one belt one road policy which benefit both countries.

Read more

Clinical Research Malaysia Signs Corruption-Free Pledge with MACC

LANGKAWI, 22 Jan – Clinical Research Malaysia (CRM), represented by 140 of its staff, signed the Corruption-Free Pledge with the MACC in a ceremony held at Berjaya Langkawi Resort today.

The signing and pledge ceremony was led by the CEO of CRM, Dr. Akhmal Yusof and witnessed by KPKPj Tuan Ruslan Tuan Mat, Deputy Director of the MACC Community Education Division.

Read more

Ministry of Health Malaysia and The Drugs for Neglected Diseases initiative (DNDi)

Clinical Research Malaysia and the Drugs for Neglected Diseases initiative Sign Agreement to Launch Clinical Studies for a Public Health Approach to Hepatitis C in Malaysia

[Putrajaya, 13 January 2016] The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.

Read more